

Narlumosbart Biosimilar - Research Grade

Product Code: ICH5261

More Information

Species Reactivity: Human

Target: TNFSF11

Concentration: 5mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Narlumosbart Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH2922

UniProt: O14788

Shipping Conditions: Blue ice

background: TNFSF11, better known as RANKL, is the principal driver of osteoclast differentiation and a central regulator of bone remodelling and immune signalling. This anti-human TNFSF11 recombinant monoclonal antibody is offered as an unconjugated, non-therapeutic analog of narlumosbart for research use only. Built to demanding in vivo specifications, it is purified to a low-endotoxin standard and manufactured in scalable milligram (mg) to gram (g) quantities suited to bulk and high-throughput work. Researchers can apply it as a dependable control and active reagent in bone biology assays, osteoclastogenesis studies, in vitro neutralization screens, and in vivo skeletal disease models.

Specificity: Detects human TNFSF11

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks